Eisai Co Ltd
Change company Symbol lookup
Select an option...
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
GPX GP Strategies Corp
AMH-E American Homes 4 Rent

Health Care : Pharmaceuticals | Large Cap Blend
Based in Japan
Company profile

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
-0.34 (-0.43%)
B/A Size
Day's High
Day's Low

10-day average volume:

Southwest Airlines' stock rises after seeing 'modest improvement' in passenger demand in August

6:53 am ET August 19, 2020 (MarketWatch)

Shares of Southwest Airlines Co. (LUV) rose 1.4% in premarket trading Wednesday, after the air carrier said that while revenue and bookings "stalled" in early July, and remain "depressed" for the rest of the month, there was "modest improvement" in close-in leisure passenger demand so far in August. The company said July revenue fell 70% to 75% from a year ago as a result of the COVID-19 pandemic, while capacity decreased 31% and load factor was about 43%, which were all in line with previous expectations. For August, Southwest expects revenue to be down 70% to 75%, capacity to fall to 27% and load factor to be in the range of 40% to 45%. The company had previously expected August revenue to drop 70% to 80%, capacity to be down 20% and load factor to be 30% to 40%. The stock has tumbled 36.7% year to date through Tuesday, while the U.S. Global Jets ETF (JETS) dropped 46.8% and the S&P 500 gained 4.9%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 19, 2020 06:53 ET (10:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.